Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
SIPPET study results published in the “New England Journal of Medicine”
This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world
CURhE, Global Alliance for mother and child healthcare
Kedrion among the founding members. The aim is Rh disease eradication
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
A brand new location for KEDPlasma donors in the very center of Fürth
Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide
KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US
The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
Humanitarian programme to reduce the gap in the access to clotting factors
Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London
5-year unrated EUR 300 million bond successfully launched
The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange
Kedrion Group approves 2013 financial statements
Achieved results of 425 million euros turnover and a 25% profitability